Tirofiban induces VEGF production and stimulates migration and proliferation of endothelial cells

Vascular Pharmacology

Volumn 61, Issue 2-3, 2014, Pages 63-71

  Giordano, Arturo ^a   D'Angelillo, Anna ^b   Romano, Simona ^b   D'Arrigo, Paolo ^b   Corcione, Nicola ^a   Bisogni, Rita ^b   Messina, Stefano ^a   Polimeno, Michele ^a   Pepino, Paolo ^a   Ferraro, Paolo ^a   Romano, Maria Fiammetta ^b  

^a Pineta Grande Hospital   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Endothelial; GPIIb IIIa; Migration; Proliferation

Indexed keywords

CYCLIN D; MITOGEN ACTIVATED PROTEIN KINASE; TIROFIBAN; VASCULOTROPIN; FIBRINOLYTIC AGENT; TYROSINE; VASCULOTROPIN A;

ARTICLE; CELL COUNT; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN AORTIC ENDOTHELIAL CELL; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; AORTA; CELL CULTURE; CELL MOTION; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

AORTA; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84900866054     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.04.002     Document Type: Article

References (21)

1. Hartman G.D., Egbertson M.S., Halczenko W., Laswell W.L., Duggan M.E., Smith R.L., et al. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J Med Chem 1992, 35:4640-4642.
2. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996, 12:697-715.
3. Hynes R. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-677.
4. Hantgan R.R., Paumi C., Rocco M., Weisel J.W. Effects of ligand-mimetic peptides Arg-Gly-Asp-X (X=Phe, Trp, Ser) on alphaIIbbeta3 integrin conformation and oligomerization. Biochemistry 1999, 38:14461-14474.
5. Ruoslahti E. Control of cell motility and tumor invasion by extra-cellular matrix interactions. Br J Cancer 1992, 66:239-242.
6. Fiume G., Vecchio E., De Laurentiis A., Trimboli F., Palmieri C., Pisano A., et al. Human immunodeficiency virus-1 Tat activates NF-κB via physical interaction with IκB-α and p65. Nucleic Acids Res 2012, 40:3548-3562.
7. Giordano A., Romano S., Monaco M., Sorrentino A., Corcione N., Di Pace A.L., et al. Differential effect of atorvastatin and tacrolimus on proliferation of vascular smooth muscle and endothelial cells. Am J Physiol Heart Circ Physiol 2012, 302:H135-H142.
8. Albini A., Benelli R. The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protoc 2007, 2:504-511.
9. Chen H.-C. Boyden chamber assay, from: methods in molecular biology. Cell Migration: Developmental Methods and Protocols 2005, vol. 294:15-22. Humana Press Inc., Totowa, NJ. J.-L. Guan © (Ed.).
10. Liang C.C., Park A.Y., Guan J.L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007, 2(2):329-333.
11. Chen S., Lee J.S., Iglesias-de la Cruz M.C., Wang A., Izquierdo-Lahuerta A., Gandhi N.K., et al. Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant 2005, 20(7):1320-8.
12. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006, 7:359-371.
13. Bonz A.W., Lengenfelder B., Strotmann J., Held S., Turschner O., Harre K., et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol 2002, 40:662-668.
14. Valgimigli M., Biondi-Zoccai G., Tebaldi M., van't Hof A.W., Campo G., Hamm C., et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J 2010, 31:35-49. (in review).
15. Valgimigli M., Percoco G., Barbieri D., Ferrari F., Guardigli G., Parrinello G., et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol 2004, 7(44):14-19.
16. Valgimigli M., Percoco G., Malagutti P., Campo G., Ferrari F., Barbieri D., et al. STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005, 293:2109-2117.
17. Bolognese L., Falsini G., Liistro F., Angioli P., Ducci K., Taddei T., et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol 2006, 47:522-528.
18. Holmes K., Roberts O.L., Thomas A.M., Cross M.J. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007, 19:2003-2012.
19. Tam S.H., Sassoli P.M., Jordan R.E., Nakada M.T. Abciximab (ReoPro, Chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and v3 integrins. Circulation 1998, 98:1085-1091.
20. Schneider D.J., Herrmann H.C., Lakkis N., Aguirre F., Lo M.W., Yin K.C., et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 2003, 91:334-336.
21. Bledzka K., Smyth S.S., Plow E.F. Integrin αIIbβ3: from discovery to efficacious therapeutic target. Circ Res 2013, 112:1189-1200.